Skip to main content
. 2017 Mar 24;61(4):e01912-16. doi: 10.1128/AAC.01912-16

TABLE 2.

Pharmacokinetic parameters of benznidazole in healthy volunteers in comparison with previously published pharmacokinetics in adultsa

Parameter Value in indicated study
This study Raaflaub and Zeigler (3) Raaflaub (4) Soy et al. (6)
No. of subjects (age range, yrs) 8 (19–32) 6 (22–24) 8 49 (19–55)
Dose 100 mg, single dose 100 mg, single dose 3.5 mg/kg/12 h, multiple doses 2.5 mg/kg/12 h, multiple doses
t1/2 (h) 12.1 (13.7–11.1) 11.7 (13–11.1) 13.75 (15–12) 36
Tmax, h (range) 3.5 (4–2.7) 3.5 (4–3)
Cmax (μg · ml−1) 2.2 (2.8–1.7) 2.61 (2.6–2.3) SS max: 12.54 (14–11) SS min: 8.02 (9.6–7.1)
AUC0–t (μg · h/ml−1) 46.4 (56.3–40.5)
AUC0–∞ (μg · h/ml−1) 48.4 (57.2–40.9)
V/F (liters) 34.5 (39.7–29.5) 89.6
CL/F (liters/h) 2.07 (2.4–1.7) 0.56 (0.6–0.5) 1.73
a

Data are reported as medians and interquartile ranges. Tmax data are shown as medians and ranges. t1/2, elimination half-life; Tmax, observed time to reach the maximum concentration in plasma; Cmax, observed maximum concentration in plasma; AUC0–t, area under the plasma drug concentration-time curve from 0 to the last measurable concentration; AUC0–∞, area under plasma drug concentration-time curve from 0 to infinity; V/F, apparent volume of distribution; CL/F, apparent oral clearance; SS max, steady-state maxima; SS min, steady-state minima.